KR20230165846A - 도파민성 전구세포 및 사용 방법 - Google Patents

Info

Publication number

KR20230165846A

KR20230165846A KR1020237038289A KR20237038289A KR20230165846A KR 20230165846 A KR20230165846 A KR 20230165846A KR 1020237038289 A KR1020237038289 A KR 1020237038289A KR 20237038289 A KR20237038289 A KR 20237038289A KR 20230165846 A KR20230165846 A KR 20230165846A

Authority

KR

South Korea

Prior art keywords

cells

culture

inhibitor

days

signaling

Prior art date

2021-04-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 321
• 210000000130 stem cell Anatomy 0.000 title claims abstract description 182
• 230000003291 dopaminomimetic effect Effects 0.000 title claims abstract description 121
• 210000004027 cell Anatomy 0.000 claims abstract description 1040
• 210000002569 neuron Anatomy 0.000 claims abstract description 204
• 210000001259 mesencephalon Anatomy 0.000 claims abstract description 86
• 208000018737 Parkinson disease Diseases 0.000 claims abstract description 71
• 210000005064 dopaminergic neuron Anatomy 0.000 claims abstract description 48
• 239000003112 inhibitor Substances 0.000 claims description 223
• 230000011664 signaling Effects 0.000 claims description 167
• 230000004069 differentiation Effects 0.000 claims description 140
• 108010087745 Hepatocyte Nuclear Factor 3-beta Proteins 0.000 claims description 93
• 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 claims description 93
• 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims description 88
• 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims description 88
• 239000012190 activator Substances 0.000 claims description 77
• 210000001577 neostriatum Anatomy 0.000 claims description 77
• 230000000977 initiatory effect Effects 0.000 claims description 64
• 102000003693 Hedgehog Proteins Human genes 0.000 claims description 52
• 108090000031 Hedgehog Proteins Proteins 0.000 claims description 52
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 claims description 48
• 230000000862 serotonergic effect Effects 0.000 claims description 43
• 101150026563 NR4A2 gene Proteins 0.000 claims description 40
• 230000001537 neural effect Effects 0.000 claims description 40
• 102000013814 Wnt Human genes 0.000 claims description 37
• 108050003627 Wnt Proteins 0.000 claims description 37
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical group C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 36
• CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical group C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 claims description 35
• 238000012258 culturing Methods 0.000 claims description 35
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 35
• 238000012360 testing method Methods 0.000 claims description 34
• 229940124647 MEK inhibitor Drugs 0.000 claims description 32
• 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 32
• 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 32
• 210000004556 brain Anatomy 0.000 claims description 29
• AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical group CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 27
• -1 SLC13A Proteins 0.000 claims description 27
• 238000002347 injection Methods 0.000 claims description 27
• 239000007924 injection Substances 0.000 claims description 27
• 239000000203 mixture Substances 0.000 claims description 26
• 238000004113 cell culture Methods 0.000 claims description 23
• 210000003523 substantia nigra Anatomy 0.000 claims description 23
• 230000002062 proliferating effect Effects 0.000 claims description 22
• 102100040290 LIM homeobox transcription factor 1-alpha Human genes 0.000 claims description 21
• 101710178355 LIM homeobox transcription factor 1-alpha Proteins 0.000 claims description 21
• 230000003115 biocidal effect Effects 0.000 claims description 21
• 201000010099 disease Diseases 0.000 claims description 21
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
• 230000035755 proliferation Effects 0.000 claims description 20
• 150000001875 compounds Chemical class 0.000 claims description 18
• 239000003550 marker Substances 0.000 claims description 17
• 239000011159 matrix material Substances 0.000 claims description 17
• 229960004857 mitomycin Drugs 0.000 claims description 17
• 208000024891 symptom Diseases 0.000 claims description 17
• 239000003242 anti bacterial agent Substances 0.000 claims description 16
• 210000002637 putamen Anatomy 0.000 claims description 16
• 108010034546 Serratia marcescens nuclease Proteins 0.000 claims description 14
• 102100039577 ETS translocation variant 5 Human genes 0.000 claims description 13
• 101150026630 FOXG1 gene Proteins 0.000 claims description 13
• 102100020871 Forkhead box protein G1 Human genes 0.000 claims description 13
• 102100021239 G protein-activated inward rectifier potassium channel 2 Human genes 0.000 claims description 13
• 101000813745 Homo sapiens ETS translocation variant 5 Proteins 0.000 claims description 13
• 101000614714 Homo sapiens G protein-activated inward rectifier potassium channel 2 Proteins 0.000 claims description 13
• 108010032788 PAX6 Transcription Factor Proteins 0.000 claims description 13
• 102100037506 Paired box protein Pax-6 Human genes 0.000 claims description 13
• 230000012010 growth Effects 0.000 claims description 13
• 238000000338 in vitro Methods 0.000 claims description 13
• 108010042407 Endonucleases Proteins 0.000 claims description 12
• 102000004533 Endonucleases Human genes 0.000 claims description 12
• 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 claims description 12
• 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 claims description 12
• 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 claims description 12
• 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 claims description 12
• 101000595674 Homo sapiens Pituitary homeobox 3 Proteins 0.000 claims description 12
• 102100023174 Methionine aminopeptidase 2 Human genes 0.000 claims description 12
• 102100036088 Pituitary homeobox 3 Human genes 0.000 claims description 12
• 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 claims description 12
• 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 11
• 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 11
• 102100027694 Homeobox protein engrailed-1 Human genes 0.000 claims description 10
• 101001081126 Homo sapiens Homeobox protein engrailed-1 Proteins 0.000 claims description 10
• 101000851865 Homo sapiens Tryptophan 5-hydroxylase 2 Proteins 0.000 claims description 10
• 239000002246 antineoplastic agent Substances 0.000 claims description 10
• LZAXPYOBKSJSEX-UHFFFAOYSA-N blebbistatin Chemical compound C1CC2(O)C(=O)C3=CC(C)=CC=C3N=C2N1C1=CC=CC=C1 LZAXPYOBKSJSEX-UHFFFAOYSA-N 0.000 claims description 10
• 229940127089 cytotoxic agent Drugs 0.000 claims description 10
• 230000006870 function Effects 0.000 claims description 10
• 230000006872 improvement Effects 0.000 claims description 10
• JMIFGARJSWXZSH-UHFFFAOYSA-N DMH1 Chemical compound C1=CC(OC(C)C)=CC=C1C1=CN2N=CC(C=3C4=CC=CC=C4N=CC=3)=C2N=C1 JMIFGARJSWXZSH-UHFFFAOYSA-N 0.000 claims description 9
• 102100024207 Transcription factor COE1 Human genes 0.000 claims description 9
• 101710182998 Transcription factor COE1 Proteins 0.000 claims description 9
• XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 claims description 9
• 210000005260 human cell Anatomy 0.000 claims description 9
• 230000033001 locomotion Effects 0.000 claims description 9
• 239000008194 pharmaceutical composition Substances 0.000 claims description 9
• 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims description 8
• 108010071690 Prealbumin Proteins 0.000 claims description 8
• 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 claims description 8
• 102000009190 Transthyretin Human genes 0.000 claims description 8
• 239000011435 rock Substances 0.000 claims description 8
• 102100027902 BarH-like 1 homeobox protein Human genes 0.000 claims description 7
• 101000697611 Homo sapiens BarH-like 1 homeobox protein Proteins 0.000 claims description 7
• 102100024200 Transcription factor COE3 Human genes 0.000 claims description 7
• 101710183003 Transcription factor COE3 Proteins 0.000 claims description 7
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
• 206010044565 Tremor Diseases 0.000 claims description 6
• 210000003169 central nervous system Anatomy 0.000 claims description 6
• 230000002518 glial effect Effects 0.000 claims description 6
• 102000045246 noggin Human genes 0.000 claims description 6
• 108700007229 noggin Proteins 0.000 claims description 6
• 238000012216 screening Methods 0.000 claims description 6
• 230000035899 viability Effects 0.000 claims description 6
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
• 102100037293 Atrial natriuretic peptide-converting enzyme Human genes 0.000 claims description 5
• 101710133555 Atrial natriuretic peptide-converting enzyme Proteins 0.000 claims description 5
• 102100027849 Homeobox protein GBX-2 Human genes 0.000 claims description 5
• 102100030636 Homeobox protein OTX1 Human genes 0.000 claims description 5
• 101000859754 Homo sapiens Homeobox protein GBX-2 Proteins 0.000 claims description 5
• 101000584392 Homo sapiens Homeobox protein OTX1 Proteins 0.000 claims description 5
• 101000720704 Homo sapiens Neuronal migration protein doublecortin Proteins 0.000 claims description 5
• 229940121849 Mitotic inhibitor Drugs 0.000 claims description 5
• 102100025929 Neuronal migration protein doublecortin Human genes 0.000 claims description 5
• 108700019146 Transgenes Proteins 0.000 claims description 5
• 229940088710 antibiotic agent Drugs 0.000 claims description 5
• 229920002674 hyaluronan Polymers 0.000 claims description 5
• 229960003160 hyaluronic acid Drugs 0.000 claims description 5
• 238000005259 measurement Methods 0.000 claims description 5
• 102100025222 CD63 antigen Human genes 0.000 claims description 4
• 102000024905 CD99 Human genes 0.000 claims description 4
• 108060001253 CD99 Proteins 0.000 claims description 4
• 102100021851 Calbindin Human genes 0.000 claims description 4
• 108020004414 DNA Proteins 0.000 claims description 4
• 229940122029 DNA synthesis inhibitor Drugs 0.000 claims description 4
• 101710181040 Endonuclease 5 Proteins 0.000 claims description 4
• 108010000722 Excitatory Amino Acid Transporter 1 Proteins 0.000 claims description 4
• 102100031563 Excitatory amino acid transporter 1 Human genes 0.000 claims description 4
• 108091006027 G proteins Proteins 0.000 claims description 4
• 102000030782 GTP binding Human genes 0.000 claims description 4
• 108091000058 GTP-Binding Proteins 0.000 claims description 4
• 206010018341 Gliosis Diseases 0.000 claims description 4
• 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 4
• 101000898082 Homo sapiens Calbindin Proteins 0.000 claims description 4
• 108010009983 Inwardly Rectifying Potassium Channels Proteins 0.000 claims description 4
• 102000009855 Inwardly Rectifying Potassium Channels Human genes 0.000 claims description 4
• 102000001435 Synapsin Human genes 0.000 claims description 4
• 108050009621 Synapsin Proteins 0.000 claims description 4
• 208000015114 central nervous system disease Diseases 0.000 claims description 4
• 230000007423 decrease Effects 0.000 claims description 4
• 239000007788 liquid Substances 0.000 claims description 4
• 101150098999 pax8 gene Proteins 0.000 claims description 4
• 230000004044 response Effects 0.000 claims description 4
• 208000011580 syndromic disease Diseases 0.000 claims description 4
• 102100032912 CD44 antigen Human genes 0.000 claims description 3
• 230000000970 DNA cross-linking effect Effects 0.000 claims description 3
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 3
• 206010052904 Musculoskeletal stiffness Diseases 0.000 claims description 3
• 101000713578 Rattus norvegicus Tubulin beta-3 chain Proteins 0.000 claims description 3
• 239000003431 cross linking reagent Substances 0.000 claims description 3
• 230000007387 gliosis Effects 0.000 claims description 3
• 229910052757 nitrogen Inorganic materials 0.000 claims description 3
• 102100022758 Glutamate receptor ionotropic, kainate 2 Human genes 0.000 claims description 2
• 101000903346 Homo sapiens Glutamate receptor ionotropic, kainate 2 Proteins 0.000 claims description 2
• 101000903313 Homo sapiens Glutamate receptor ionotropic, kainate 5 Proteins 0.000 claims description 2
• 208000007101 Muscle Cramp Diseases 0.000 claims description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 2
• 208000005392 Spasm Diseases 0.000 claims description 2
• 208000002173 dizziness Diseases 0.000 claims description 2
• 208000010118 dystonia Diseases 0.000 claims description 2
• 238000007710 freezing Methods 0.000 claims description 2
• 230000008014 freezing Effects 0.000 claims description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 claims description 2
• 230000002110 toxicologic effect Effects 0.000 claims description 2
• 231100000027 toxicology Toxicity 0.000 claims description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
• 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims 8
• 102100037680 Fibroblast growth factor 8 Human genes 0.000 claims 8
• 102000001267 GSK3 Human genes 0.000 claims 4
• 108060006662 GSK3 Proteins 0.000 claims 4
• NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims 4
• 239000004971 Cross linker Substances 0.000 claims 1
• 108010048671 Homeodomain Proteins Proteins 0.000 claims 1
• 102000009331 Homeodomain Proteins Human genes 0.000 claims 1
• 101000892398 Homo sapiens Tryptophan 2,3-dioxygenase Proteins 0.000 claims 1
• 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 claims 1
• 239000008177 pharmaceutical agent Substances 0.000 claims 1
• 238000011282 treatment Methods 0.000 abstract description 42
• 230000001976 improved effect Effects 0.000 abstract description 16
• 239000002243 precursor Substances 0.000 abstract description 11
• 208000014644 Brain disease Diseases 0.000 abstract description 9
• 239000002609 medium Substances 0.000 description 155
• 241001465754 Metazoa Species 0.000 description 55
• 241000700159 Rattus Species 0.000 description 52
• 230000014509 gene expression Effects 0.000 description 47
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 42
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 38
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 38
• 229940112869 bone morphogenetic protein Drugs 0.000 description 38
• 210000001778 pluripotent stem cell Anatomy 0.000 description 38
• 230000030214 innervation Effects 0.000 description 32
• 230000008569 process Effects 0.000 description 30
• 238000001727 in vivo Methods 0.000 description 27
• 210000004263 induced pluripotent stem cell Anatomy 0.000 description 27
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 25
• 108090000623 proteins and genes Proteins 0.000 description 24
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 24
• 238000002054 transplantation Methods 0.000 description 23
• 241000699666 Mus <mouse, genus> Species 0.000 description 22
• 230000000694 effects Effects 0.000 description 22
• 238000003753 real-time PCR Methods 0.000 description 22
• 229960003638 dopamine Drugs 0.000 description 21
• 238000000684 flow cytometry Methods 0.000 description 21
• 230000035800 maturation Effects 0.000 description 21
• 210000001519 tissue Anatomy 0.000 description 21
• 230000003542 behavioural effect Effects 0.000 description 19
• 230000004083 survival effect Effects 0.000 description 18
• 238000002474 experimental method Methods 0.000 description 17
• 238000011084 recovery Methods 0.000 description 17
• 210000001671 embryonic stem cell Anatomy 0.000 description 16
• 210000002950 fibroblast Anatomy 0.000 description 15
• 238000001543 one-way ANOVA Methods 0.000 description 15
• 210000004129 prosencephalon Anatomy 0.000 description 15
• 230000001225 therapeutic effect Effects 0.000 description 15
• 238000003556 assay Methods 0.000 description 14
• 230000015572 biosynthetic process Effects 0.000 description 14
• 229960000632 dexamfetamine Drugs 0.000 description 14
• 239000001963 growth medium Substances 0.000 description 14
• 238000003365 immunocytochemistry Methods 0.000 description 14
• 230000006698 induction Effects 0.000 description 14
• 230000003902 lesion Effects 0.000 description 14
• 238000004458 analytical method Methods 0.000 description 13
• 239000000835 fiber Substances 0.000 description 13
• 239000003102 growth factor Substances 0.000 description 13
• 230000001965 increasing effect Effects 0.000 description 13
• DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 13
• 230000006735 deficit Effects 0.000 description 12
• 210000005155 neural progenitor cell Anatomy 0.000 description 12
• 210000002966 serum Anatomy 0.000 description 12
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 11
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 11
• 101001062354 Xenopus tropicalis Forkhead box protein A2 Proteins 0.000 description 11
• 229940025084 amphetamine Drugs 0.000 description 11
• 238000011161 development Methods 0.000 description 11
• 230000018109 developmental process Effects 0.000 description 11
• 238000004519 manufacturing process Methods 0.000 description 11
• 238000000059 patterning Methods 0.000 description 11
• 238000010186 staining Methods 0.000 description 11
• 239000000758 substrate Substances 0.000 description 11
• 230000002354 daily effect Effects 0.000 description 10
• 239000000463 material Substances 0.000 description 10
• 230000003287 optical effect Effects 0.000 description 10
• 102000004169 proteins and genes Human genes 0.000 description 10
• 230000008672 reprogramming Effects 0.000 description 10
• 238000004114 suspension culture Methods 0.000 description 10
• 238000010257 thawing Methods 0.000 description 10
• 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 9
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 9
• 102100036474 Tryptophan 5-hydroxylase 2 Human genes 0.000 description 9
• 210000002459 blastocyst Anatomy 0.000 description 9
• 238000011002 quantification Methods 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 210000001082 somatic cell Anatomy 0.000 description 9
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 8
• 206010043276 Teratoma Diseases 0.000 description 8
• 239000007943 implant Substances 0.000 description 8
• 210000001178 neural stem cell Anatomy 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• 239000003981 vehicle Substances 0.000 description 8
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 241000282412 Homo Species 0.000 description 7
• 102000004058 Leukemia inhibitory factor Human genes 0.000 description 7
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 7
• 238000010171 animal model Methods 0.000 description 7
• 238000013459 approach Methods 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 230000024245 cell differentiation Effects 0.000 description 7
• 230000004663 cell proliferation Effects 0.000 description 7
• 230000001413 cellular effect Effects 0.000 description 7
• 239000003814 drug Substances 0.000 description 7
• 210000002242 embryoid body Anatomy 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 238000010166 immunofluorescence Methods 0.000 description 7
• 238000002513 implantation Methods 0.000 description 7
• 230000001939 inductive effect Effects 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 102000039446 nucleic acids Human genes 0.000 description 7
• 108020004707 nucleic acids Proteins 0.000 description 7
• 150000007523 nucleic acids Chemical class 0.000 description 7
• 241000766026 Coregonus nasus Species 0.000 description 6
• 208000012661 Dyskinesia Diseases 0.000 description 6
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
• 108010085895 Laminin Proteins 0.000 description 6
• 102000007547 Laminin Human genes 0.000 description 6
• 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 6
• 230000002776 aggregation Effects 0.000 description 6
• 238000004220 aggregation Methods 0.000 description 6
• 238000000540 analysis of variance Methods 0.000 description 6
• 230000003466 anti-cipated effect Effects 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 210000004002 dopaminergic cell Anatomy 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
• 238000012423 maintenance Methods 0.000 description 6
• 108010082117 matrigel Proteins 0.000 description 6
• 210000003061 neural cell Anatomy 0.000 description 6
• 230000004770 neurodegeneration Effects 0.000 description 6
• 230000007832 reinnervation Effects 0.000 description 6
• 150000003384 small molecules Chemical class 0.000 description 6
• 210000004281 subthalamic nucleus Anatomy 0.000 description 6
• 102000000905 Cadherin Human genes 0.000 description 5
• 108050007957 Cadherin Proteins 0.000 description 5
• 108010035532 Collagen Proteins 0.000 description 5
• 102000008186 Collagen Human genes 0.000 description 5
• 108010076089 accutase Proteins 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 102000014823 calbindin Human genes 0.000 description 5
• 108060001061 calbindin Proteins 0.000 description 5
• 239000006285 cell suspension Substances 0.000 description 5
• 238000012512 characterization method Methods 0.000 description 5
• 229920001436 collagen Polymers 0.000 description 5
• 239000012091 fetal bovine serum Substances 0.000 description 5
• 238000011534 incubation Methods 0.000 description 5
• 210000001161 mammalian embryo Anatomy 0.000 description 5
• 210000004245 medial forebrain bundle Anatomy 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 208000015122 neurodegenerative disease Diseases 0.000 description 5
• 230000009207 neuronal maturation Effects 0.000 description 5
• 238000007747 plating Methods 0.000 description 5
• 102000040430 polynucleotide Human genes 0.000 description 5
• 108091033319 polynucleotide Proteins 0.000 description 5
• 239000002157 polynucleotide Substances 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 108010088751 Albumins Proteins 0.000 description 4
• 102000009027 Albumins Human genes 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 239000012583 B-27 Supplement Substances 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• 206010006100 Bradykinesia Diseases 0.000 description 4
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 4
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 4
• 241001269524 Dura Species 0.000 description 4
• 108010067306 Fibronectins Proteins 0.000 description 4
• 102000016359 Fibronectins Human genes 0.000 description 4
• 102000038624 GSKs Human genes 0.000 description 4
• 108091007911 GSKs Proteins 0.000 description 4
• 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 4
• 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 4
• 208000006083 Hypokinesia Diseases 0.000 description 4
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
• 108010009583 Transforming Growth Factors Proteins 0.000 description 4
• 102000009618 Transforming Growth Factors Human genes 0.000 description 4
• 102000004142 Trypsin Human genes 0.000 description 4
• 108090000631 Trypsin Proteins 0.000 description 4
• 238000004115 adherent culture Methods 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 4
• 210000004720 cerebrum Anatomy 0.000 description 4
• 230000004186 co-expression Effects 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 238000011109 contamination Methods 0.000 description 4
• 230000002596 correlated effect Effects 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 238000010494 dissociation reaction Methods 0.000 description 4
• 230000005593 dissociations Effects 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 230000001605 fetal effect Effects 0.000 description 4
• 210000001654 germ layer Anatomy 0.000 description 4
• 238000003364 immunohistochemistry Methods 0.000 description 4
• 238000010348 incorporation Methods 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 210000005036 nerve Anatomy 0.000 description 4
• 108010055896 polyornithine Proteins 0.000 description 4
• 239000013641 positive control Substances 0.000 description 4
• 238000010149 post-hoc-test Methods 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 230000001737 promoting effect Effects 0.000 description 4
• 238000010791 quenching Methods 0.000 description 4
• 238000009256 replacement therapy Methods 0.000 description 4
• 238000010374 somatic cell nuclear transfer Methods 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
• 238000012546 transfer Methods 0.000 description 4
• 239000012588 trypsin Substances 0.000 description 4
• 239000013598 vector Substances 0.000 description 4
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
• 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 3
• DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 3
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
• 239000012981 Hank's balanced salt solution Substances 0.000 description 3
• 101000595669 Homo sapiens Pituitary homeobox 2 Proteins 0.000 description 3
• 206010061598 Immunodeficiency Diseases 0.000 description 3
• 102000004877 Insulin Human genes 0.000 description 3
• 108090001061 Insulin Proteins 0.000 description 3
• 238000012313 Kruskal-Wallis test Methods 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 3
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
• 102000005640 Myosin Type II Human genes 0.000 description 3
• 108010045128 Myosin Type II Proteins 0.000 description 3
• 108010025020 Nerve Growth Factor Proteins 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• 102100036090 Pituitary homeobox 2 Human genes 0.000 description 3
• 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 229910000831 Steel Inorganic materials 0.000 description 3
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 3
• 102000004338 Transferrin Human genes 0.000 description 3
• 108090000901 Transferrin Proteins 0.000 description 3
• 108010031318 Vitronectin Proteins 0.000 description 3
• 102100035140 Vitronectin Human genes 0.000 description 3
• 210000001130 astrocyte Anatomy 0.000 description 3
• 210000003050 axon Anatomy 0.000 description 3
• 239000007640 basal medium Substances 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 230000010261 cell growth Effects 0.000 description 3
• 238000002659 cell therapy Methods 0.000 description 3
• 210000004748 cultured cell Anatomy 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 238000011977 dual antiplatelet therapy Methods 0.000 description 3
• 230000009977 dual effect Effects 0.000 description 3
• 210000002257 embryonic structure Anatomy 0.000 description 3
• 210000003754 fetus Anatomy 0.000 description 3
• 230000003371 gabaergic effect Effects 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 229940125396 insulin Drugs 0.000 description 3
• 230000002147 killing effect Effects 0.000 description 3
• 101150111214 lin-28 gene Proteins 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 238000013411 master cell bank Methods 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 210000001009 nucleus accumben Anatomy 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 230000000644 propagated effect Effects 0.000 description 3
• 238000011552 rat model Methods 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 210000001202 rhombencephalon Anatomy 0.000 description 3
• 239000010959 steel Substances 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 239000013589 supplement Substances 0.000 description 3
• 239000012581 transferrin Substances 0.000 description 3
• 238000012800 visualization Methods 0.000 description 3
• HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
• FHCSBLWRGCOVPT-UHFFFAOYSA-N AZD2858 Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C(=O)NC=2C=NC=CC=2)C=C1 FHCSBLWRGCOVPT-UHFFFAOYSA-N 0.000 description 2
• 108010036280 Aquaporin 4 Proteins 0.000 description 2
• 102000012002 Aquaporin 4 Human genes 0.000 description 2
• 102100026376 Artemin Human genes 0.000 description 2
• CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 2
• 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
• 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
• 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
• 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• 108010053770 Deoxyribonucleases Proteins 0.000 description 2
• 102000016911 Deoxyribonucleases Human genes 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 101000873546 Homo sapiens Glutamate decarboxylase 1 Proteins 0.000 description 2
• 101000702391 Homo sapiens Protein sprouty homolog 1 Proteins 0.000 description 2
• 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 101150107947 Kcnj6 gene Proteins 0.000 description 2
• 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• IBCXZJCWDGCXQT-UHFFFAOYSA-N LY 364947 Chemical compound C=1C=NC2=CC=CC=C2C=1C1=CNN=C1C1=CC=CC=N1 IBCXZJCWDGCXQT-UHFFFAOYSA-N 0.000 description 2
• 101100285407 Mus musculus En1 gene Proteins 0.000 description 2
• 101000616468 Mus musculus Sonic hedgehog protein Proteins 0.000 description 2
• 102000015336 Nerve Growth Factor Human genes 0.000 description 2
• 108010088225 Nestin Proteins 0.000 description 2
• 102000008730 Nestin Human genes 0.000 description 2
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
• 108010070047 Notch Receptors Proteins 0.000 description 2
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• 102100030399 Protein sprouty homolog 1 Human genes 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• PQCXVIPXISBFPN-UHFFFAOYSA-N SB 415286 Chemical compound C1=C(Cl)C(O)=CC=C1NC1=C(C=2C(=CC=CC=2)[N+]([O-])=O)C(=O)NC1=O PQCXVIPXISBFPN-UHFFFAOYSA-N 0.000 description 2
• 108091006283 SLC17A7 Proteins 0.000 description 2
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
• 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 238000010162 Tukey test Methods 0.000 description 2
• 102100038039 Vesicular glutamate transporter 1 Human genes 0.000 description 2
• 102100023550 Zinc finger protein 42 homolog Human genes 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 238000013019 agitation Methods 0.000 description 2
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
• 230000000735 allogeneic effect Effects 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 229960004046 apomorphine Drugs 0.000 description 2
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000012829 chemotherapy agent Substances 0.000 description 2
• 230000001143 conditioned effect Effects 0.000 description 2
• 238000007428 craniotomy Methods 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000001627 detrimental effect Effects 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 210000003981 ectoderm Anatomy 0.000 description 2
• 230000007831 electrophysiology Effects 0.000 description 2
• 238000002001 electrophysiology Methods 0.000 description 2
• 210000001900 endoderm Anatomy 0.000 description 2
• 239000003797 essential amino acid Substances 0.000 description 2
• 235000020776 essential amino acid Nutrition 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 210000002758 humerus Anatomy 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 229940100601 interleukin-6 Drugs 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 210000003716 mesoderm Anatomy 0.000 description 2
• 210000000274 microglia Anatomy 0.000 description 2
• 230000002025 microglial effect Effects 0.000 description 2
• 230000000394 mitotic effect Effects 0.000 description 2
• 229940053128 nerve growth factor Drugs 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 210000005055 nestin Anatomy 0.000 description 2
• 210000004498 neuroglial cell Anatomy 0.000 description 2
• 230000004031 neuronal differentiation Effects 0.000 description 2
• 239000002581 neurotoxin Substances 0.000 description 2
• 231100000618 neurotoxin Toxicity 0.000 description 2
• 230000005868 ontogenesis Effects 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 101150093695 pitx3 gene Proteins 0.000 description 2
• 230000001144 postural effect Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 210000002442 prefrontal cortex Anatomy 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
• 239000002994 raw material Substances 0.000 description 2
• 210000000463 red nucleus Anatomy 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 238000000611 regression analysis Methods 0.000 description 2
• 229930002330 retinoic acid Natural products 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 229910052711 selenium Inorganic materials 0.000 description 2
• 239000011669 selenium Substances 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 230000002295 serotoninergic effect Effects 0.000 description 2
• 239000012679 serum free medium Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 238000010245 stereological analysis Methods 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 229960001727 tretinoin Drugs 0.000 description 2
• 210000000143 trophectoderm cell Anatomy 0.000 description 2
• 230000007306 turnover Effects 0.000 description 2
• LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
• 238000011714 129 mouse Methods 0.000 description 1
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
• GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 1
• RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 1
• JCSGFHVFHSKIJH-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-4-(1-methyl-3-indolyl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C1=CC=C(Cl)C=C1Cl JCSGFHVFHSKIJH-UHFFFAOYSA-N 0.000 description 1
• ZGXOBLVQIVXKEB-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-N,N-dimethyl-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N(C)C)O ZGXOBLVQIVXKEB-UHFFFAOYSA-N 0.000 description 1
• VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 description 1
• VFSUUTYAEQOIMW-UHFFFAOYSA-N 3-chloro-n-[4-(methylamino)cyclohexyl]-n-[(3-pyridin-4-ylphenyl)methyl]-1-benzothiophene-2-carboxamide Chemical compound C1CC(NC)CCC1N(C(=O)C1=C(C2=CC=CC=C2S1)Cl)CC1=CC=CC(C=2C=CN=CC=2)=C1 VFSUUTYAEQOIMW-UHFFFAOYSA-N 0.000 description 1
• DXLXRNZCYAYUED-UHFFFAOYSA-N 4-[2-[4-(3-quinolin-4-ylpyrazolo[1,5-a]pyrimidin-6-yl)phenoxy]ethyl]morpholine Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=CC=1OCCN1CCOCC1 DXLXRNZCYAYUED-UHFFFAOYSA-N 0.000 description 1
• UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
• 101150053137 AIF1 gene Proteins 0.000 description 1
• BLTVBQXJFVRPFK-UHFFFAOYSA-N AZD1080 Chemical compound OC=1NC2=CC=C(C#N)C=C2C=1C(N=C1)=CC=C1CN1CCOCC1 BLTVBQXJFVRPFK-UHFFFAOYSA-N 0.000 description 1
• 108010059616 Activins Proteins 0.000 description 1
• 102100026882 Alpha-synuclein Human genes 0.000 description 1
• 101710205806 Artemin Proteins 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 238000010152 Bonferroni least significant difference Methods 0.000 description 1
• MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 description 1
• 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 1
• 241000288950 Callithrix jacchus Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000202252 Cerberus Species 0.000 description 1
• 102100025745 Cerberus Human genes 0.000 description 1
• 101710010675 Cerberus Proteins 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
• 102000038900 DAN family Human genes 0.000 description 1
• 108091065053 DAN family Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 101001027406 Danio rerio Fibroblast growth factor 8b Proteins 0.000 description 1
• 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 102100031785 Endothelial transcription factor GATA-2 Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 241000289669 Erinaceus europaeus Species 0.000 description 1
• 102100037733 Fatty acid-binding protein, brain Human genes 0.000 description 1
• 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
• 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
• 108010014612 Follistatin Proteins 0.000 description 1
• 102000016970 Follistatin Human genes 0.000 description 1
• 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
• 102100038367 Gremlin-1 Human genes 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
• 102100021154 Homeobox protein DBX1 Human genes 0.000 description 1
• 102100039542 Homeobox protein Hox-A2 Human genes 0.000 description 1
• 101000785776 Homo sapiens Artemin Proteins 0.000 description 1
• 101001066265 Homo sapiens Endothelial transcription factor GATA-2 Proteins 0.000 description 1
• 101001027674 Homo sapiens Fatty acid-binding protein, brain Proteins 0.000 description 1
• 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 description 1
• 101001041021 Homo sapiens Homeobox protein DBX1 Proteins 0.000 description 1
• 101000962636 Homo sapiens Homeobox protein Hox-A2 Proteins 0.000 description 1
• 101100348043 Homo sapiens NCAM1 gene Proteins 0.000 description 1
• 101001109698 Homo sapiens Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 description 1
• 101001094741 Homo sapiens POU domain, class 4, transcription factor 1 Proteins 0.000 description 1
• 101001129803 Homo sapiens Paired mesoderm homeobox protein 2A Proteins 0.000 description 1
• 101000836765 Homo sapiens Protein amnionless Proteins 0.000 description 1
• 101000900786 Homo sapiens Protein canopy homolog 1 Proteins 0.000 description 1
• 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
• 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 description 1
• 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 1
• 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
• 102100026818 Inhibin beta E chain Human genes 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000014429 Insulin-like growth factor Human genes 0.000 description 1
• 108091006975 Iron transporters Proteins 0.000 description 1
• 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• HRJWTAWVFDCTGO-UHFFFAOYSA-N LY-2090314 Chemical compound C1CN(C=23)C=C(C=4C(NC(=O)C=4C=4N5C=CC=CC5=NC=4)=O)C3=CC(F)=CC=2CN1C(=O)N1CCCCC1 HRJWTAWVFDCTGO-UHFFFAOYSA-N 0.000 description 1
• 201000002832 Lewy body dementia Diseases 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 108090000143 Mouse Proteins Proteins 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• 208000001089 Multiple system atrophy Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
• 101100310645 Mus musculus Sox15 gene Proteins 0.000 description 1
• 101100310650 Mus musculus Sox18 gene Proteins 0.000 description 1
• 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 1
• 239000012580 N-2 Supplement Substances 0.000 description 1
• VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 1
• FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
• 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 1
• 101710138657 Neurotoxin Proteins 0.000 description 1
• 102100021584 Neurturin Human genes 0.000 description 1
• 108010015406 Neurturin Proteins 0.000 description 1
• 102000014736 Notch Human genes 0.000 description 1
• 102000005650 Notch Receptors Human genes 0.000 description 1
• 102100022676 Nuclear receptor subfamily 4 group A member 2 Human genes 0.000 description 1
• 206010030312 On and off phenomenon Diseases 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• DXCUKNQANPLTEJ-UHFFFAOYSA-N PD173074 Chemical compound CC(C)(C)NC(=O)NC1=NC2=NC(NCCCCN(CC)CC)=NC=C2C=C1C1=CC(OC)=CC(OC)=C1 DXCUKNQANPLTEJ-UHFFFAOYSA-N 0.000 description 1
• 101150031628 PITX2 gene Proteins 0.000 description 1
• 102100035395 POU domain, class 4, transcription factor 1 Human genes 0.000 description 1
• 102100031686 Paired mesoderm homeobox protein 2A Human genes 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 108010009736 Protein Hydrolysates Proteins 0.000 description 1
• 102100027097 Protein amnionless Human genes 0.000 description 1
• 102100022051 Protein canopy homolog 1 Human genes 0.000 description 1
• 101001021643 Pseudozyma antarctica Lipase B Proteins 0.000 description 1
• 239000005700 Putrescine Substances 0.000 description 1
• 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 102000005038 SLC6A4 Human genes 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 102000019355 Synuclein Human genes 0.000 description 1
• 108050006783 Synuclein Proteins 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 108091005735 TGF-beta receptors Proteins 0.000 description 1
• 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102100030248 Transcription factor SOX-1 Human genes 0.000 description 1
• 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
• 206010060872 Transplant failure Diseases 0.000 description 1
• 102100029290 Transthyretin Human genes 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 210000001642 activated microglia Anatomy 0.000 description 1
• 239000000488 activin Substances 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 108090000185 alpha-Synuclein Proteins 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 208000037875 astrocytosis Diseases 0.000 description 1
• 230000007341 astrogliosis Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 210000001142 back Anatomy 0.000 description 1
• 239000003855 balanced salt solution Substances 0.000 description 1
• 210000004227 basal ganglia Anatomy 0.000 description 1
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
• 238000009227 behaviour therapy Methods 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
• 238000013406 biomanufacturing process Methods 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
• 229960005263 bucladesine Drugs 0.000 description 1
• 230000009172 bursting Effects 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 210000001159 caudate nucleus Anatomy 0.000 description 1
• 230000004956 cell adhesive effect Effects 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 230000001713 cholinergic effect Effects 0.000 description 1
• 108010008846 chordin Proteins 0.000 description 1
• 102000006533 chordin Human genes 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 229960002271 cobimetinib Drugs 0.000 description 1
• RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
• 230000006999 cognitive decline Effects 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 210000000877 corpus callosum Anatomy 0.000 description 1
• 238000012136 culture method Methods 0.000 description 1
• 238000009109 curative therapy Methods 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 238000007822 cytometric assay Methods 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000001784 detoxification Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 230000008923 dopaminergic innervation Effects 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 238000007878 drug screening assay Methods 0.000 description 1
• 230000008406 drug-drug interaction Effects 0.000 description 1
• 230000002900 effect on cell Effects 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 239000012595 freezing medium Substances 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 239000003540 gamma secretase inhibitor Substances 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000003633 gene expression assay Methods 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 238000010363 gene targeting Methods 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
• 210000001905 globus pallidus Anatomy 0.000 description 1
• 230000000848 glutamatergic effect Effects 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 238000009499 grossing Methods 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940124589 immunosuppressive drug Drugs 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 230000003447 ipsilateral effect Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 230000010198 maturation time Effects 0.000 description 1
• 238000010297 mechanical methods and process Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 230000028161 membrane depolarization Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 101150094317 mfd gene Proteins 0.000 description 1
• 108091070501 miRNA Proteins 0.000 description 1
• 239000002679 microRNA Substances 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000001000 micrograph Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000000921 morphogenic effect Effects 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 239000003471 mutagenic agent Substances 0.000 description 1
• 231100000707 mutagenic chemical Toxicity 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 238000003291 neural activity measurement Methods 0.000 description 1
• 230000003988 neural development Effects 0.000 description 1
• 230000007472 neurodevelopment Effects 0.000 description 1
• 230000004766 neurogenesis Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 230000007514 neuronal growth Effects 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 239000003900 neurotrophic factor Substances 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000012758 nuclear staining Methods 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 210000002475 olfactory pathway Anatomy 0.000 description 1
• 210000001010 olfactory tubercle Anatomy 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 238000000424 optical density measurement Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000001050 pharmacotherapy Methods 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 229920002714 polyornithine Polymers 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 238000013105 post hoc analysis Methods 0.000 description 1
• 230000001242 postsynaptic effect Effects 0.000 description 1
• 231100000316 potential neurotoxicity Toxicity 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 210000002243 primary neuron Anatomy 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 239000003531 protein hydrolysate Substances 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• FYBHCRQFSFYWPY-UHFFFAOYSA-N purmorphamine Chemical compound C1CCCCC1N1C2=NC(OC=3C4=CC=CC=C4C=CC=3)=NC(NC=3C=CC(=CC=3)N3CCOCC3)=C2N=C1 FYBHCRQFSFYWPY-UHFFFAOYSA-N 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 102000037983 regulatory factors Human genes 0.000 description 1
• 108091008025 regulatory factors Proteins 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 229960003471 retinol Drugs 0.000 description 1
• 235000020944 retinol Nutrition 0.000 description 1
• 239000011607 retinol Substances 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 238000007860 single-cell PCR Methods 0.000 description 1
• 210000001626 skin fibroblast Anatomy 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000007655 standard test method Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 238000002636 symptomatic treatment Methods 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 210000003478 temporal lobe Anatomy 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• PMJIHLSCWIDGMD-UHFFFAOYSA-N tideglusib Chemical compound O=C1SN(C=2C3=CC=CC=C3C=CC=2)C(=O)N1CC1=CC=CC=C1 PMJIHLSCWIDGMD-UHFFFAOYSA-N 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 238000002723 toxicity assay Methods 0.000 description 1
• 231100000041 toxicology testing Toxicity 0.000 description 1
• 239000011573 trace mineral Substances 0.000 description 1
• 235000013619 trace mineral Nutrition 0.000 description 1
• LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 239000012808 vapor phase Substances 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 150000003722 vitamin derivatives Chemical class 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1